There are currently 283 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Cancer participants are California, Texas, New York and Florida.
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793
Recruiting
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +8 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Register for Updates
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Urology Centers of Alabama, PC, Homewood, Alabama +381 locations
Conditions: Cancer
Register for Updates
Rare Tumors and Cancer Predisposition in Individuals and Families
NCT05350761
Recruiting
Background: Some people may be prone to develop cancer for many reasons. Factors that affect their risk include the genes they inherit and the environment they live and work in. Researchers want to learn more about the natural history of cancer. Objective: To understand how genes and environmental factors can cause tumors and related conditions. Eligibility: People of any age who: Have tumors of an unusual type, pattern, or number Have a family member with a history of cancer Have been e... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Cancer, Hereditary Neoplasms, Genetic Predisposition to Cancer, Environment
Register for Updates
Long-Term Follow-Up of Recipient of Gene Transfer Research
NCT01492036
Recruiting
The goal of this clinical research study is to collect information about the long-term safety of gene transfer therapy. This study is also designed to create a database of medical information about patients who have received gene transfer therapy, in order for researchers to track and review the long-term safety and any effects (good or bad) of gene transfer therapy.
Gender:
ALL
Ages:
All
Trial Updated:
07/30/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Retroviridae Infections, Cancer
Register for Updates
MAAT For Young Adult Cancer Survivors
NCT06150976
Recruiting
The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measure... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/29/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana +2 locations
Conditions: Cancer
Register for Updates
Dyadic Life Review Intervention for Older Patients With Advanced Cancer) and Their Caregivers
NCT06505122
Recruiting
The purpose of this study is to test the feasibility of a pilot Randomized Controlled Trial (RCT) comparing Dyadic Life Review (DLR) intervention in older adults with advanced cancer and their caregivers to Care-as-Usual (CAU) group, which involves a referral to social work.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/29/2025
Locations: University of Rochester, Rochester, New York
Conditions: Cancer
Register for Updates
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
NCT06451003
Recruiting
While blood clots after major cancer surgery are common and harmful to patients, the medications to decrease blood clot risk are seldom used after patients leave the hospital despite the recommendation of multiple professional medical societies. The reason why these medications are seldom prescribed is not well understood. The main questions this study aims to answer are: * Does surgeon education paired with an electronic medical record based decision support tool improve the guideline concorda... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Register for Updates
Cancer Survivor Cardiomyopathy Detection
NCT05201014
Recruiting
The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/28/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cardiovascular Diseases, Cancer
Register for Updates
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
NCT05789589
Recruiting
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida
Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Register for Updates
A Study of Live Tumor Fragments of Surgical Resections
NCT07000864
Recruiting
The purpose of this study is to obtain unused resected tumor tissue sample and associated clinical data from patients enrolled in this study to research ex vivo treatment response and integrity of tumor microenvironment using omics analysis and imaging while maintaining cell stability in a live environment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Cancer, Tumor
Register for Updates
Examining the Feasibility and Impact of a Clinic-based Food Farmacy and Digital Culinary Medicine Program Among Cancer Survivors Treated in a Safety Net Hospital
NCT06760754
Recruiting
The goal of this study is to develop and test the feasibility of a theory-driven digital culinary medicine program among food insecure cancer survivors referred from the University of Texas MD Anderson Cancer Center Oncology Clinic at LBJ to the LBJ Food Farmacy program.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Cancer
Register for Updates
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
NCT05378425
Recruiting
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: City of Hope, Duarte, California +5 locations
Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Register for Updates